propranolol has been researched along with pentamidine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brun, R; Buckner, FS; Chatterjee, AK; Creason, SA; Duster, NA; Gelb, MH; Gillespie, JR; Glynne, R; Hulverson, MA; McQueen, J; Molteni, V; Nagendar, P; Nagle, A; Norcross, NR; Ranade, RM; Supek, F; Tatipaka, HB; Wenzler, T | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Buckner, FS; Gelb, MH; Gillespie, JR; Herbst, ZM; Montanari, CA; Nguyen, UTT; Ranade, RM; Silva, DG | 1 |
| Bacchi, CJ; Braillard, S; Chatelain, E; Denny, WA; Gaukel, E; Launay, D; Maes, L; Marshall, AJ; Mowbray, CE; Thompson, AM; Wring, SA; Yarlett, N | 1 |
| Ang, CW; Avery, VM; Blaskovich, MAT; Butler, MS; Cooper, MA; Debnath, A; Hahn, HJ; Jarrad, AM; Jones, AJ; Karoli, T; Pelingon, R; Sykes, ML; Tan, L; West, NP; Woods, K | 1 |
1 review(s) available for propranolol and pentamidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for propranolol and pentamidine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis.
Topics: Administration, Oral; Animals; Biological Availability; Cell Line, Tumor; Cell Membrane Permeability; Databases, Chemical; Dogs; Female; Humans; Imidazoles; Madin Darby Canine Kidney Cells; Mice; Microsomes, Liver; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense; Trypanosomiasis, African | 2014 |
New Class of Antitrypanosomal Agents Based on Imidazopyridines.
Topics: | 2017 |
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Nitroimidazoles; Small Molecule Libraries; Structure-Activity Relationship; Trypanosomiasis, African | 2018 |
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.
Topics: Animals; Antiparasitic Agents; Antitubercular Agents; Caco-2 Cells; Drug Design; Drug Evaluation, Preclinical; Drug Stability; Entamoeba histolytica; Giardia lamblia; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Nitroimidazoles; Structure-Activity Relationship | 2018 |